Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $69.5 million.

  • Tango Therapeutics' Cash & Equivalents rose 9.77% to $58.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.3 million, marking a year-over-year increase of 9.77%. This contributed to the annual value of $69.5 million for FY2024, which is 0.40% down from last year.
  • Per Tango Therapeutics' latest filing, its Cash & Equivalents stood at $69.5 million for FY2024, which was down 0.40% from $69.8 million recorded in FY2023.
  • In the past 5 years, Tango Therapeutics' Cash & Equivalents ranged from a high of $145.0 million in FY2021 and a low of $30.7 million during FY2020.
  • In the last 3 years, Tango Therapeutics' Cash & Equivalents had a median value of $69.5 million in 2024 and averaged $66.4 million.
  • As far as peak fluctuations go, Tango Therapeutics' Cash & Equivalents soared by 373.01% in 2021, and later crashed by 58.65% in 2022.
  • Tango Therapeutics' Cash & Equivalents (Yearly) stood at $30.7 million in 2020, then spiked by 373.01% to $145.0 million in 2021, then plummeted by 58.65% to $60.0 million in 2022, then grew by 16.41% to $69.8 million in 2023, then decreased by 0.40% to $69.5 million in 2024.